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Treatment of Salmonella meningitis: two case reports 
and a review of the literature 
Alex Owusu-Ofori@,*) and W. Michael Scheld(2,3) 
Background: Salrnonellu species now represent a leading cause of Gram-negative bacterial meningitis in the 
developing world. Various drugs have been used for the treatment of Sulmonellu meningitis over the past decades, 
but mortality, neurologic sequelae and relapse rates remain high. In this report we describe two children aged 8 and 
9 months who presented within a week to our hospital with Salmonella meningitis. They were treated with penicillin 
and chloramphenicol but progressed rapidly to death within 48 h. 
Aim: The aim of this article is to review all published English literature on the treatment of Salmonella meningitis 
and identify the best drug option for its treatment. This was done by comparing the outcomes such as cure, failure, 
relapse, and death rates. 
Method: A Medline electronic search was carried out to find and retrieve articles that have been published since 
1987, when the last review of Salmonella meningitis was done. 
Results: Salmonellu typhimurium was the commonest organism reported, and 89.7% of infections occurred in 
children less than 1 year old. Fluoroquinolones had a cure rate of 88.9%, while the third-generation cephalosporins 
had a cure rate of 84.6%. Conventional antibiotics (chloramphenicol, ampicillin, and cotrimoxazole) had a cure rate 
of 41.2%, a relapse rate of 11.8%, and an associated mortality of 44.7%.Treatment with fluoroquinolone and imipenem 
resulted in no deaths. There were, however, only two cases that were treated with imipenem. 
Conclusion: When Salmonellu meningitis is suspected, third-generation cephalosporins, with or without a fluoro- 
quinolone, may be the best option for treatment. 
Int J Infect Dis 2003; 7: 53-60 
INTRODUCTION 
Salmonellu meningitis is an unusual manifestation of 
salmonellosis.* It is, however, relatively common in 
developing countries, although rarely seen in developed 
ones.2-6 Salmonella spp. comprise a leading cause of 
Gram-negative aerobic bacillary meningitis in infants 
in Latin America.7,8 In Africa, Salmonella now ranks 
fourth after Streptococcus pneumoniae, Haemophilus 
injluenzae and Neiseria meningitidis as a cause of 
meningitis in children.9 That it is a seriously emerging 
problem cannot be disputed, as Salmonella spp. now 
account for 13% of cases of childhood bacterial menin- 
gitis’O and are some of the leading organisms respon- 
sible for serious infections in young African infants.l’ 
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Salmonella meningitis is a major cause of death and 
brain damage in many parts of the world.12J3 Salmonella 
meningitis is associated with a particularly poor prog- 
nosis,4J2J4 as patients are more likely to die from 
Salmonellu meningitis than from meningitis due to the 
other major bacterial pathogens.15 
Treatment of Salmonella meningitis is very difficult, 
and has never been standardized. Various drugs have 
been used during recent decades, including chloram- 
phenicol, ampicillin, cotrimoxazole, third-generation 
cephalosporins, and fluoroquinolones. We report in this 
paper two cases of Salmonella meningitis that presented 
within a week of each other and rapidly progressed to 
death. We also review the recent published literature on 
the treatment of Salmonella meningitis. 
METHODOLOGY 
We carried out an electronic search of the Medline 
database for articles that have appeared since 1987, 
when the last review of Salmonella meningitis was done. 
Search words and terms used included Salmonella 
meningitis, Gram-negative bacterial meningitis, salmon- 
ellosis, Salmonella infections, meningitis, and Salmonella. 
All articles containing any information on a patient who 
was diagnosed with Salmonella meningitis were then 
retrieved for review and analysis. 
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CASE 1 
An S-month-old boy presented on 24 July 2000 to 
the outpatient department of Komfo Anokye Teaching 
Hospital with a complaint of fever which had persisted 
for 3 days despite standard antimalarial treatment with 
chloroquine and paracetamol. Neither the child nor any 
family members had a history of diarrhea, but a day 
prior to admission the child began to vomit. 
The patient was undernourished, weighing 6.8 kg. 
His axillary temperature on admission was 37S°C, 
and his respiratory rate was 40/min. His pulse rate was 
147/min and regular. Abdominal examination revealed 
splenomegaly of 3 cm. He was conscious, the neck 
was supple, and Kernig’s and Brudzinski’s signs were 
negative. The child was detained at the recovery ward 
on suspicion of chloroquine-resistant malaria, and was 
started on amodiaquine even though no malaria para- 
sites were seen. He was sickle-cell negative, and his 
hemoglobin level was 9.8 g/dL. Eighteen hours later, 
he had a convulsion, with a temperature of 37.6”C. 
The seizure was described as tonic-clonic, lasted for 
about 5 min, and was controlled with 3 mg of rectal 
diazepam. The blood glucose level was between 70 and 
130 mg/dL. 
The child was then transferred to the pediatric ward, 
and a lumbar puncture was performed. The cerebro- 
spinal fluid (CSF) was turbid and under pressure, so 
a diagnosis of bacterial meningitis was made, and the 
patient was started on parenteral penicillin, chloram- 
phenicol, and dexamethasone. Amodiaquine was changed 
to quinine, and 10% intravenous dextrose was added. 
The child had no more convulsions, but died 12 h after 
admission. The CSF culture was positive for SaZmoneZlu, 
which was sensitive to gentamicin and ceftriaxone and 
resistant to chloramphenicol. 
CASE 2 
A 9-month old girl was admitted on 31 July 2000 to the 
pediatric ward in an unconscious state. Her mother 
reported a 2-day history of diarrhea and vomiting, for 
which the child had been receiving oral rehydration 
solution. On the night prior to admission, the patient 
developed a fever, and the mother sponged the child and 
gave her paracetamol. The next morning, the child had 
a generalized tonic-clonic seizure that lasted for more 
than 1.5 min, after which the child did not regain con- 
sciousness and fever persisted. 
A random check on admission revealed zero blood 
sugar, so the child was resuscitated with 25% dextrose 
bolus and maintained on 10% dextrose. Her modified 
Glasgow coma score did not improve beyond 215, despite 
her blood glucose being maintained above 130 mg/dL. 
She was febrile on examination (38”C), and not de- 
hydrated. There were no petechiae, and there was no 
jaundice, but she was slightly pale. Abdominal findings 
were unremarkable, and the pulse was 108/min and 
regular. There was no neck stiffness, and Kernig’s sign 
was negative. The patient was sickle-cell negative, and 
the hematocrit was 24%. 
On lumbar puncture, however, the CSF was 
xanthochromic, with a cell count of 520/mm3, mainly 
neutrophils, and culture results obtained after 48 h 
identified the organism as Salmonella, resistant to ampi- 
cillin, chloramphenicol and gentamicin, but sensitive to 
ceftriaxone. 
The patient was treated for both cerebral malaria 
and meningitis with quinine, chloramphenicol and 
penicillin, but died 25 h following admission. 
RESULTS 
The findings of 23 publications on Salmonella menin- 
gitis, which have appeared since Kinsella et all6 reviewed 
the treatment of Salmonella meningitis in 1987, are sum- 
marized in Tables l-6. 
DISCUSSION AND COMMENTS 
There has been a recent increase in extraintestinal 
salmonellosis,*7 especially meningitis,15 and Salmonella 
meningitis is becoming an important clinical entity. 
Some have attributed the rise in cases to the increase in 
the number of cases of HIV infection.i5 In our teaching 
hospital in Ghana, an average of 20 pediatric cases of 
Salmonella meningitis has been seen each year over the 
past 3 years (Adjei 0. Personal communication). Humans 
acquire Salmonella by ingestion of contaminated food 
or water, and gastroenteritis remains the most common 
clinical presentation. Focal infections such as meningitis 
follow bacteremia, which occurs as a result of migration 
Table 1. Serotypes of salmonellae isolated from cerebrospinal 
fluid 
Sub-group Number of cases Percentage (%) 
5. typhimurium 53/l 04 51 
5. enteritidis 171104 16 
Salmonella spp. 61104 6 
5. Panama 31104 3 
5. bredeney 3/104 3 
5. infantis 21104 2 
5. virchow 21104 2 
5. sandiego 21104 2 
5. newport 21104 2 
Twelve other species were isolated, and each accounted for 1% of the total 
number of cases. 
Table 2. Clinical features seen in Sa/mone//a meningitis 
Clinical features Number of cases Percentage (“/o) 
Malnutrition 51157 91 
High fever 35148 73 
Anemia 619 67 
Seizures 26142 62 
Diarrhea 24144 55 
Vomiting 8123 34 
Respiratory distress 319 33 
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of the organisms across the gastrointestinal tract into the 
bloodstream. 
Serotypes 
The distribution of Salmonella serotypes, isolated from 
patients with meningitis, is shown in Table 1. The sero- 
types isolated appear similar to those that have been 
reported over the past three decades. Of those currently 
among the top five serotypes in our review, Salmonella 
typhimurium, Salmonella enteritidis and Salmonella 
Panama were noted to be among the top five in 1962,‘s 
while Salmonella typhimurium, Salmonella enteritidis, 
Salmonella newport and Salmonella infantis were among 
the leading species in 1969.19 In a report from the 
Centers for Disease Control published in 1981,2” these 
same serotypes, together with Salmonella heidelberg 
and Salmonella saint-Paul, accounted for most of the 
salmonellae isolated from the CSF of patients in the 
USA. Salmonella typhimurium was the leading cause of 
meningitis, and accounted for more than half of the 
species (Table 1). Fifty-one of the 53 cases of Salmonella 
typhimurium infection were from one study from 
Malawi. Salmonella enteritidis was next in frequency of 
occurrence. Six of the organisms could not be speciated. 
The pattern of serotypes isolated from CSF is similar 
to the pattern seen in bacteremia,21 and we therefore 
believe that no serotype has a particular predilection for 
the central nervous system. 
Age distribution 
Young children remain the age group that is predomi- 
nantly affected. Of the 126 patients reviewed, only two 
(1.6%) were older than 2 years. Furthermore, 89.7% 
were less than a year old. A few authors chose to use age 
ranges, thus making it impossible to review for specific 
ages. The trend, however, shows clearly that the majority 
of cases are from a few days old to a few weeks old. A 
CDC report showed that a third of patients yielding 
Salmonella isolates from the CSF were younger than 
3 months, and more than half were younger than 1 
year.20 Many reasons, including an immature blood- 
brain barrier and a poorly developed immune system, 
have been postulated for why young children are most 
susceptible, but no single explanation is adequate. 
Clinical features 
Table 2 gives an indication of the presentations that 
were frequently associated with Salmonella meningitis 
cases. Some authors did not give full clinical details, and 
therefore the signs and symptoms listed in the table may 
not be comprehensive, as they represent only those that 
were specifically mentioned. Malnutrition was the most 
common observation (91%). High fever, which repre- 
sents temperature greater than 39°C was the next most 
frequent presentation. Also included in the group of 
cases with high fever were those cases for which the 
Table 3. Recent published reports on the treatment of Salmonella meningitis with conventional antibiotics (chloramphenicol, 
ampicillin and cotrimoxazole) 
Drug Dose Duration Age Cured Failed Relapse Died Author Country 
Chloramph IV 
Oral 
Cotrim IV 
Oral 
Amp+Gent+ IV 
Cotrim 
Chloramph+Cotrim 
+cefoperazone 
Amp+ IV 
Chloramph 
Amp+Ceft+ IV 
Chloramph 
Chloramph Oral 
Cotrim 
Cotrim+Amp 
Amp+Chloramph 
Amp+Gent 
Amp+Cefo 
Amp+Cotrim 
Amp+Amikacin 
Amp+ 
Cefu 
Amp+ 
Chloramph 
Unknown combination 
All <2years 19 
2-3 weeks (except I) 
2 weeks 4 months 1 
2 weeks 
3 days 
24 days 2 months 1 
3-13 weeks 8 days to 
5 months 
2 weeks 4 months 1 
16 weeks 
6 weeks 1 
6 weeks 1 
4 weeks 
4 weeks 
4 weeks 
4 weeks 4 
Zldays 
10 days 
4 days 
26 days 
9 days 
7 
Tota I 35 
(%I (41.2) 
2 33 Molyneux et alZ2 
Lee et al 28 
2 2 1 
Visudhiphan et al23 Thailand 
1 Kavaliotis et al2g 
1 1 
1 Unhanand et a130 
1 
2 
(2.4) (‘?I .8) fJ4.64.6, 
Malawi 
Malaysia 
Greece 
USA 
Amp. amPicirlin; chloramph. chloramphenicol; Cotrim, cotrimoxazole; Gent, gentamicin; Cefo, cefotaxime; Cefu, cefuroxime. 
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Table 4. Recent published reports on the treatment of Salmonella meningitis with third-generation cephalosporins 
Drug 
Route1 
Dose Duration Age Cure Failure Relapse Died Author Country 
Cefo+Gent ’ >3 weeks 3 weeks to 4 months 5 
22 days 27 days 
25 days 1 
5 weeks 
26 days 3 months 
7 days 
6 weeks 9 months 
2 months 
Cefo 
Cefo+NetiI 
Ceft 100 mglkglday 
Ceft+ IV 
Chloramph IV 
Ceftz+Amp 
Cefo+netiI 
keft) IV 
Cefo 
Cefo 200 mg/kg/day 
Cefo+Cotrim 
Cefo 200 mg/kg 
Ceft 
Cefo 
Ceftz 
Cefo 
Cefo+Gent 
Cefo+Amp 
Cefo+Z others 
Cefo+amp+genta 
Cefo+ 
Cipro 10 mg/kg 
Cefo+ 200 mglkglday 
Amp 200 mglkglday 
Cefo+Cotrim 
CefolCeftz 
Cefo+ 140 mg/kg/day 
Amp 200 mglkglday 
Ceft+Amp+ 
Netil 
Cefo 200 mg/kg/day 
Total 
1 
2 
1 
1 
21 days 17 days 
6-8 weeks 1.5-6 months 
1 
8 
2 
3 weeks 5 months 
8 weeks 6 months 
4 weeks 
28 days 28 days 
21 days 2-3 months 
21 days 5 months 
21-42 days 21 days to 2 years 
21-33 days 2-l 1 months 
6 days 4 weeks 
21 days 6 weeks 
14 days 
3 weeks 
3 days 
4 weeks 
2 weeks 10 days 
21 days 11 days 
22 days 
21-28 days 3 days to 3 months 
1 
1 
2 
1 
9 
2 
1 
1 
1 
1 
2 
43 
(96) (83.0) 
lspahani and Slade3* UK 
Sam and Mackay33 UK 
Kayemba et al34 France 
Chiu35 Taiwan 
Lee et al28 Malaysia 
1 
Vasquez-Lopez et al7 
1 Visudhiphan et al23 
1 
1 Paton and Mirfattahi3‘j 
Lu et a13’ 
1 Koc et a13* 
Huang et al3g 
1 
1 Hansen et a140 Denmark 
Huang et a14’ Taiwan 
Kavaliotis et al2g Greece 
1 Bhutta et aI” Pakistan 
1 Kostiala et al43 Finland 
Soe and Overturf 
75.6) ;17.6) t3.8) 
Spain 
Thailand 
UK 
Taiwan 
Turkey 
Taiwan 
USA 
Cefo, cefotaxime; Ceft, ceftriaxone; Ceftz, ceftazidime; Amp, ampicillin; Chloramph, chloramphenicol; Cotrim, cotrimoxazole; Gent, gentamicin; Cipro, 
ciprofloxacin; Netil, netilmicin. 
Table 5. Recent published reports on the treatment of Salmonella meningitis with fluoroquinolones 
Drug Dose Duration Age Cure Failure Relapse Died Author Country 
Cipro+Ceft 3 weeks 4 months 1 Lee et al 28 Malaysia 
Cipro+Ceft+ 9 weeks 9 months 1 
Chloramph 
Cipro+ 50 mglkglday 15 days 21 days 1 Krcmery et a14’ Slovak 
3rd Gen Ceph 10 days 
Cipro+ 30 mglkglday 16 months 1 Kim et al48 Korea 
Ceft 100 mglkglday 
Cipro+ 30 mglkglday 4 weeks 2 Visudhiphan et al23 Thailand 
Cefo 200 mglkglday 6 weeks 
Cipro+Cefo 3 weeks 5 months 1 Paton and Mirfattahi36 UK 
Cipro+ 12 mgikglday 8 days 
Amikacin 30 mg/kg/day 1 Bhutta et al4g Pakistan 
Cipro 10 mglkg1b.i.d. 3 weeks 1 Bhutta et al42 Pakistan 
Cipro 25 mglkg/b.i.d. 6 days 1 Ragnnathan et al 5o UK 
Total 9 
(%I (88.9) 211.1) 0 0 
Cipro, ciprofloxacin; Ceft, ceftriaxone; Cefo, cefotaxime; Chloramph, chloramphenicol; 3rd Gen Ceph, third-generation cephalosporin; b.i.d, twice daily. 
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Table 6. Recent published reports on the treatment of Salmonella meningitis with imipenem 
Drug Dose Duration Age Cured Failed Relapse Died Author Country 
lmipenem+ 45 mglkglday 6 weeks IOdays 1 Bhutta4g Pakistan 
Amikacin 5 weeks 
lmipenem 1 Koc et a13’ Turkey 
Total 2 0 0 0 
authors did not give a value but simply reported that 
there was a high fever. Anemia, seizures and diarrhea 
were the other clinical features, and occurred in more 
than half of the patients. 
AIDS was clinically suspected in 16% of a group of 
children in a study from Malawi.22 Sickle-cell disease has 
long been associated with Salmonella infectionsi but, 
surprisingly, none of the authors reported Salmonella 
meningitis in this group of children. 
Treatment 
Salmonella meningitis is at present difficult to treat.23 
The conventional antibiotics recommended for therapy 
of Salmonella infections (chloramphenicol, ampicillin, 
or cotrimoxazole) have been used for decades, and 
continue to be utilized for Salmonella meningitis, despite 
unsatisfactory results. I6 In a recently completed study in 
Malawi, Molyneux et al reported a mortality rate of 58% 
in 61 Salmonella meningitis cases, with the development 
of neurologic sequelae in 8.1% .20 This was despite the in 
vitro sensitivities of the isolates, suggesting susceptibility 
to chloramphenicol. Bryan and Scheld in 199224 showed 
in rabbits with experimental Salmonella meningitis that 
chloramphenicol is not effective. One of the problems 
with chloramphenicol is that it is bacteriostatic against 
Salmonella?5 and so is not suitable for treatment of Sal- 
monella meningitis, an infection in an area of impaired 
host resistance.* Optimum management of bacterial 
meningitis requires antibiotic(s) with bactericidal 
action.26 Another problem that makes chloramphenicol 
unsuitable is its effect on the bone marrow. Since 
Salmonella meningitis must be treated for about 4 weeks, 
there is a greater chance of causing bone marrow sup- 
pression and subsequent anemia. In a case report by 
Rabinowitz et a1T7 two of their three patients who were 
receiving chloramphenicol had to change antibiotics 
when their hematocrit fell. Prolonged use of chloram- 
phenicol in infants is therefore not desirable. Since in- 
fants account for the bulk of Salmonella meningitis 
cases, chloramphenicol is not a good option for treat- 
ment. 
As can be seen from Table 3,22,23,28-3o chloram- 
phenicol is not clinically effective in the treatment of 
Salmonella meningitis. It continues to be used in many 
developing countries as a first-line drug, because it is 
inexpensive and easily available, unlike other newer and 
effective drugs. Such agents are more efficacious and 
available, but not easily affordable.31 Table 3 again shows 
that, generally, the conventional antibiotics used either 
singly or in combination do not achieve a good clinical 
response. However, 88% of those who received co- 
trimoxazole (usually in combination with other agents) 
were cured. It must be noted that the number taking 
cotrimoxazole, singly or in combination, were small 
(9 treated, 8 survived), and therefore it is difficult to 
draw valid conclusions. Unfortunately, ampicillin and 
chloramphenicol, alone or combined, did not give such 
good results. 
Bryan and Scheld compared ampicillin, chloram- 
phenicol and cotrimoxazole with ceftriaxone and 
imipenem in an experimental model of Salmonella 
meningitis in the rabbit, and found that only the latter 
agents rapidly sterilized the CSF.24 They recommended 
a further evaluation of these agents in humans. Since 
then, several reports have been published on the use of 
cephalosporins, but relatively little on imipenem 
treatment of Salmonella meningitis. 
Cephalosporins have been used to treat Salmonella 
meningitis, with appreciable success, despite some 
reports of failure and relapse (Table 4).1*23*28,29,32~ Most 
of the published papers are case reports of one or 
two patients, although the Thai study23 and the Taiwan 
study39 together include an analysis of 27 patients. 
In the Thai study, six infants were successfully 
treated with cefotaxime, but the report was not very 
specific on the occurrence of neurologic sequelae. 
Neurologic sequelae have not been included in Table 4, 
because it is difficult to determine whether these com- 
plications reflect the disease, its treatment or both, and 
reporting of their occurrence is infrequent, with short- 
term or no follow-up, in most studies from developing 
countries. Since there are more survivors with the newer 
drugs, more complications may be noted than with the 
older drugs, since early deaths remove these patients 
from the pool that may develop sequelae. Generally, 
Salmonella meningitis is associated with a high incidence 
of complications. 12*28,41 Some of the factors associated 
with poor outcomes include late presentation and pro- 
longed fever.22,‘9 
In one of the largest published clinical experiences 
with third-generation cephalosporins, cefotaxime was 
used as the primary drug in 15 children;39 two patients 
received cefotaxime alone, while another seven patients 
remained on cefotaxime alone after the results of their 
susceptibility tests were known. Only one child died, and 
no relapses were reported. Cefotaxime and ceftriaxone 
have been the most frequently used cephalosporins, 
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but the duration of treatment of children varied from 
3 to 8 weeks;23,39 most of the long treatment courses 
were for Salmonella cerebral abscesses, in concert 
with surgical drainage. 37 Emerging resistance to third- 
generation cephalosporins is a cause for concern, how- 
ever.45 Furthermore, the cephalosporins have not always 
produced excellent results, as reported by Lecour et al 
in their study of childhood meningitis, where the case- 
fatality rate for Salmonella meningitis was 28.6%.46 
In addition, there is one case report from Turkey of 
relapsing Salmonella meningitis38 following a 4-week 
course of cefotaxime. 
The combination of cephalosporins with other anti- 
biotics also appears to have produced favorable results. 
Most patients have received multiple drugs, as docu- 
mented in several clinical case reports. The Thai example 
reported two infants being treated successfully with 
cefotaxime and cotrimoxazole. 
The use of fluoroquinolones for the therapy of 
Salmonella meningitis (Table 5),23,28,36,42,47-50 particularly 
ciprofloxacin, has gradually increased over the past 
decade, especially in cases where there appears to be 
no clinical improvement with other antibiotics.48,51,52 
Fluoroquinolones have potential activity against several 
multiresistant organisms, including difficult-to-treat 
organisms such as Salmonella.53 
In most of the cases employing fluoroquinolones, a 
third-generation cephalosporin was given in combina- 
tion with ciprofloxacin. Visudhiphan et al used cipro- 
floxacin with success in two patients who did not 
respond clinically to cefotaxime for 2 weeks.23 It is worth 
noting that ciprofloxacin was added to cefotaxime and 
the combination given for 4 weeks. Kim et al also added 
ciprofloxacin to their initial treatment with ceftriaxone 
and amikacin in a 16-month-old girl who was deterio- 
rating clinically. 48 One of the main concerns in using 
ciprofloxacin is its potential joint toxicity and cartilage 
destruction in children, but such effects have not been 
reported in humans. In fact, a 4-week-old infant who had 
meningitis and multiple cerebral abscesses caused by 
Salmonella enteritidis was treated with a prolonged 
course of ciprofloxacin without any joint toxicity being 
detected.54 Furthermore, a consensus report of an 
International Society of Chemotherapy commission on 
the use of fluoroquinolones in pediatric patients indi- 
cated that prolonged therapy with the fluoroquinolones 
is effective and well tolerated, with no significant 
evidence of arthropathy, bone abnormality, or other 
serious adverse events.53 
A potential advantage of fluoroquinolones is the 
near 100% bioavailability following oral administration, 
excellent penetration into many tissues (including CSF 
and brain), and good intracellular diffusion, which may 
provide efficacy against an intracellular organism like 
Salmonella that also requires prolonged treatment. 
There is, however, an urgent need for additional 
controlled studies in pediatric patients to define the role 
of fluoroquinolones in the treatment of serious Gram- 
negative infections, with attention to safety concerns, 
which are vital for this age group. Until then, quinolones 
should be used with caution. 
Carbapenems, because of potent in vitro activity 
against Salmonella, may be useful for the treatment of 
meningitis. These agents also have good CSF pharma- 
cokinetic properties. For example, imipenem penetration 
into CSF in an experimental animal study was the 
highest of the agents investigated (41%) and, like 
ceftriaxone, imipenem had the lowest minimum in- 
hibitory concentration against Salmonella isolates from 
CSF.24 Imipenem is, however, associated with seizures,55 
and should generally be avoided for the treatment of 
central nervous system infections. Nevertheless, there 
have been two reported cases of successful treatment of 
Salmonella meningitis with imipenem (Table 6).38,49 For 
example, Bhutta used it at a dose of 45 mg/kg per day 
for 5 weeks in combination with amikacin to treat a lo- 
day-old premature infant successfully.49 
In view of the frequent concomitant use of anti- 
biotics, it is difficult to evaluate the agents critically for 
monotherapy of Salmonella meningitis. The combina- 
tion of ciprofloxacin and cefotaxime or ceftriaxone has 
been suggested for the treatment of Salmonella menin- 
gitis.56 We believe that this combination will be the 
treatment of choice in the near future, when ciprofloxacin 
is approved for use in children without any controversy. 
COMMENTS ON CASE REPORTS 
It is possible that had our two patients been started on a 
third-generation cephalosporin, they may have survived, 
especially as both isolates were resistant to chloram- 
phenicol but sensitive to these agents. These two 
unfortunate cases with early death reveal the poor 
prognosis of Salmonella meningitis. The case mortality 
in childhood Salmonella meningitis in Africa is between 
39% and 58%,‘0~‘4~22 and is even worse in neonates, with 
a case-fatality rate of 89% in recent studies.i5 
On the basis of our review, Salmonella meningitis 
should be suspected in a febrile infant presenting with 
seizures, diarrhea and vomiting, and anemia. Malnutrition 
and AIDS/HIV are the other conditions that should lead 
one to suspect Salmonella meningitis. Both of our cases 
were anemic but sickle-cell negative, and their HIV status 
was not determined. While case 1 was malnourished, 
case 2 presented with diarrhea. We suggest that, despite 
the high cost of third-generation cephalosporins, these 
agents be encouraged as first-line drugs for the therapy 
of presumed or proven Salmonella meningitis. 
CONCLUSION 
Meningitis due to Salmonella spp. is associated with a 
very high mortality. Our review suggests that the con- 
ventional antibiotics (e.g. ampicillin, chloramphenicol, 
or cotrimoxazole) have a minimal role in the treatment 
of Salmonella meningitis, and there is a need for more 
clinical experience with third-generation cephalo- 
Treatment of Salmonella meningitis: two case reports and a review of the literature I Owusu-Ofori et al 59 
sporins, fluoroquinolones, and perhaps meropenem. 
In view of the increasing incidence of Salmonella 
meningitis in developing countries and other parts of the 
world, we suggest that in all cases of bacterial meningitis 
in infants, where the suspicion is high as in those with 
predisposing or risk factors, Salmonella should be 
seriously considered and treatment should start with 
a third-generation cephalosporin, with or without a 
fluoroquinolone. In cases where these drugs cannot be 
afforded, cotrimoxazole may be considered. When con- 
firmed, Salmonella meningitis should probably be 
treated for at least 4 weeks. 
REFERENCES 
1. Vasquez-Lopez ME, Pego R, Somoza C, Garcia-Plata C, 
Rodriguez-De La Riva P, Morales-Redondo R. Meningitis 
due to Salmonella in the neonatal period. Rev Neurol 
1998; 27(160):986-987. 
2. Low LC, Lam BC, Wong WT, Chan-Lui WY, Yeung CY. 
Salmonella meningitis in infancy. Aust Paediatr J 1984; 
20(3):225-228. 
3. Appelbaum PC, Scragg J. Salmonella meningitis in infants 
[Letter]. Lancet 1977; 1(8020):1052-1053. 
4. Davis RC. Salmonella sepsis in infancy. Am J Dis Child 
1981; 135(12):1096-1099. 
5. Cherubin CE, Marr JS, Sierra MF, Becker S. Listeria 
and gram-negative bacillary meningitis in New York City, 
1972-1979. Frequent causes of meningitis in adults. Am J 
Med 1981; 71(2):199-209. 
6. Rodriguez RE, Valero V, Watanakunakorn C. Salmonella 
focal intracranial infections: review of the world literature 
(1884-1984) and report of an unusual case. Rev Infect Dis 
1986; 8(1):31-41. 
7. McCracken GH Jr, Mize SG,Threlkeld N. Intraventricular 
gentamicin therapy in gram-negative bacillary meningitis 
of infancy. Report of the Second Neonatal Meningitis 
Cooperative Study Group. Lancet 1980; 1(8172):787-791. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
Bryan JP, da Silva HR,Tavares A, Sande MA, Scheld WM. 
Etiology of and mortality from bacterial meningitis in 
northeastern Brazil. Rev Infect Dis 1990; 12:128-135. 
Peltola H. Burden of meningitis and other severe bacterial 
infections of children in Africa: implications for prevention. 
Clin Infect Dis 2001; 32:64-75. 
Salaun-Saraux P, Saraux A, Lepage P, et al. Septic 
meningitis in children in Rwanda from 1983 to 1990. Retro- 
spective study at the Kigali Hospital Center. Med Trop 
1995; 55(1):4145. 
Mulholland EK, Ogunlesi 00, Adegbola RA, et al. 
Etiology of serious infections in young Gambian infants. 
Pediatr Infect Dis J 1999; 18( 10 Suppl):S35-S41. 
Cohen A, Freundlich E, Greif Z. Nontyphoid salmonella 
septicemia. Harefuah 1987; 112(1):5-7. 
West SE, Goodkin R, Kaplan AM. Neonatal salmonella 
meningitis complicated by cerebral abscesses. West J Med 
1977; 127(2):142-145. 
Koko J, Dufillot D, Kani F, Gahouma D, Reymond-Yeni 
A. Salmonella meningitis in children in Libreville. Retro- 
spective study of 9 cases. Arch Pediatr 1997; 4(12):1175- 
1181. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. 
30. 
31. 
32. 
33. 
34. 
Molyneux E, Walsh A, Phiri A, Molyneux M. Acute 
bacterial meningitis in children admitted to the Queen 
Elizabeth Central Hospital, Blantyre, Malawi in 1996-97. 
Trop Med Int Health 1998; 3(8):610-618. 
Kinsella TR, Yogev R, Shulman ST, Gilmore R, Chadwick 
EG. Treatment of Salmonella meningitis and brain abscess 
with the new cephalosporins: two case reports and a review 
of the literature. Pediatr Infect Dis J 1987; 6(5):476-480. 
Schutze GE, Schutze SE, Kirby RS. Extraintestinal 
salmonellosis in a children’s hospital. Pediatr Infect Dis J 
1997; 16(5):482485. 
Riley HD, Deardoff M. Salmonella meningitis. J Oklahoma 
State Med Assoc 1962; 55:10-18. 
Loewenstein MS, Fox MD, Martin SM. Surveillance for 
Salmonella-1969. J Infect Dis 1971; 123(3):332-334. 
Wilson R, Feldman R. Reported isolates of Salmonella 
from cerebrospinal fluid in the United States. 1968-1979. 
J Infect Dis 1981; 143(3):504-506. 
Cotton MF, Burger PJ, Bodenstein WJ. Bacteraemia in 
children in the south-western Cape. A hospital-based 
survey. S Afr Med J 1992; 81(2):87-90. 
Molyneux EM, Walsh AL, Malenga G, Rogerson S, 
Molyneux ME. Salmonella meningitis in children in 
Blantyre, Malawi, 1996-1999. Ann Trop Paediatr 2000: 
20( 1):4144. 
Visudhiphan P Chiemchanya S, Visutibhan A. Salmonella 
meningitis in Thai infants: clinical case reports. Trans R Sot 
Trop Med Hyg 1998; 92(2):181-184. 
Bryan JP, Scheld WM. Therapy of experimental meningitis 
due to Salmonella enteritidis. Antimicrob Agents Chemo- 
ther 1992; 36(5):949-954. 
Preblub SR, Gill CJ, Campos JM. Bactericidal activities 
of chloramphenicol and eleven other antibiotics against 
Salmonella spp. Antimicrob Agents Chemother 1984; 25(3): 
327-330. 
Scheld WM. Rationale for optimal dosing of beta-lactam 
antibiotics in the therapy for bacterial meningitis. Eur J 
Clin Microbial 1984; 3(6):579-591. 
Rabinowitz SG, MacLeod NR. Salmonella meningitis. A 
report of three cases and review of the literature. Am J Dis 
Child 1972; 123(3):259-262. 
Lee WS, Puthucheary SD, Omar A. Salmonella meningitis 
and its complications in infants. J Paediatr Child Health 
1999; 35(4):379-382. 
Kavaliotis J, Tsiauusi A, Papavasiliou D, Kansouzidou A. 
Non-typhoid Salmonella meningitis. Stand J Infect Dis 
1994; 26(4):403-405. 
Unhanand M, Mustafa MM, McCracken GH Jr, Nelson 
JD. Gram-negative enteric bacillary meningitis: a twenty- 
one-year experience. J Pediatr 1993; 122(1):15-21. 
Hart CA, Kariuki S. Antimicrobial resistance in develop- 
ing countries. BMJ 1998; 317(7159):647-650. 
Ispahani P, Slack RC. Enteric fever and other extra- 
intestinal salmonellosis in University Hospital, Nottingham, 
UK, between 1980 and 1997. Eur J Clin Microbial Infect 
Dis 2000; 19(9):679-687. 
Sam WI, Mackay AD. Salmonella meningitis and a green 
iguana. J R Sot Med 2000; 93(6):318-319. 
Kay’s Kayemba S, Raobijoana H, Francois P, Croize 
J, Bost-Bru C. Acute Salmonella typhi meningitis in a 
25-day-old newborn infant complicated by obstruction of 
the sylvian artery. Arch Pediatr 2000; 7(2):154157. 
60 International Journal of Infectious Diseases I Volume 7, Number 1,2003 
35. Chiu C-H. Persistence of Salmonella species in the 
cerebrospinal fluid of patients with meningitis following 
ceftriaxone therapy. Clin Infect Dis 1999; 28:1174-1175. 
36. Paton JH, Mirfattahi MB. Salmonella meningitis acquired 
from pet snakes. Arch Dis Child 1997; 77(1):93. 
37. Lu CS, Chiu CH, Lin TY, Lin SL. Salmonella typhimurium 
brain abscess in a six-month-old infant: a case report and 
review of the literature. Chang Keng I Hsueh 1997,20(3): 
219-225. 
38. Koc E, Turkyilmaz C, Atalay Y, Sen E. Imipenem for 
treatment of relapsing Salmonella meningitis in a newborn 
infant. Acta Paediatr Jpn 1997; 39(5):62&625. 
39. Huang LT, Ko SF, Lui CC. Salmonella meningitis: clinical 
experience of third-generation cephalosporins. Acta Pae- 
diatr 1997; 86(10):1056-1058. 
40. Hansen LN, Eschen C, Bruun B. Neonatal Salmonella menin- 
gitis: two case reports. Acta Paediatr 1996; 85(5): 629-631. 
41. Huang LT. Salmonella meningitis complicated by brain 
infarctions. Clin Infect Dis 1996; 22(1):194-195. 
42. Bhutta ZA, Farooqui BJ, Sturm AW. Eradication of 
a multiple drug resistant Salmonella paratyphi A causing 
meningitis with ciprofloxacin. J Infect 1992; 25(2):215- 
219. 
43. Kostiala AA, Westerstrahle M, Muttilainen M. Neonatal 
Salmonellapanama infection with meningitis. Acta Paediatr 
1992; 81(10):856-858. 
44. Soe GB, Overturf GD. Treatment of typhoid fever and 
other systemic salmonelloses with cefotaxime, ceftriaxone, 
cefoperazone, and other newer cephalosporins. Rev Infect 
Dis 1987; 9(4):719-736. 
45. Vahaboglu H, Hall LM, Mulazimoglu L, Dodanli S, 
Yildirim I, Livermore DM. Resistance to extended- 
spectrum cephalosporins, caused by PER-l beta-lactamase, 
in Salmonella typhimurium from Istanbul, Turkey. J Med 
Microbial 1995; 43(4):294-299. 
46. Lecour H, Seara A, Cordeiro J, Miranda M. Treatment of 
childhood bacterial meningitis. Infection 1989; 17(5):343- 
346. 
47. Krcmery V Jr, Filka J, Uher J, et al. Ciprofloxacin in treat- 
ment of nosocomial meningitis in neonates and in infants: 
report of 12 cases and review. Diagn Microbial Infect Dis 
1999; 35(1):75-80. 
48. Kim H, Jeoung JY, Ham SY, Kim SR. Non-typhoid 
Salmonella meningitis complicated by an infarction of 
basal ganglia. J Korean Med Sci 1999; 14(3):342-344. 
49. Bhutta ZA. Quinolone-resistant Salmonella paratyphi B 
meningitis in a newborn: a case report. J Infect 1997; 35(3): 
308-310. 
50. Ragunathan PL, Potkins DV, Watson JG, Kearns AM, 
Carroll A. Neonatal meningitis due to Salmonella typhi- 
murium treated with ciprofloxacin [Letter]. J Antimicrob 
Chemother 1990; 26(5):727-728. 
51. Wessalowski R, Thomas L, Kivit J, Voit T. Multiple brain 
abscesses caused by Salmonella enteritidis in a neonate: 
successful treatment with ciprofloxacin. Pediatr Infect Dis 
J 1993; 16:683-688. 
52. Lewin CS. Treatment of multiresistant Salmonella in- 
fections. Lancet 1991; 337:47. 
53. Schaad UB, Salam MA, Aujard Y, et al. Use of fluoro- 
quinolones in paediatrics: consensus report of an Inter- 
national Society of Chemotherapy commission. Pediatr 
Infect Dis J 1995; 14(1):1-9. 
54. Workman MR, Price EH, Bullock P Salmonella meningitis 
and multiple cerebral abscesses in an infant. Int J Anti- 
microb Agents 1999; 13(2):131-132. 
55. Wong VK, Wright HT, Ross LA, Mason WH, Inderlied CB, 
Kim KS. Imipenem/cilastatin treatment of bacterial 
meningitis in children. Pediatr Infect Dis J 1991; lO(2): 
122-125. 
56. Price EH, De Louvois J, Workman MR. Antibiotics for 
Salmonella meningitis in children. J Antimicrob Chemother 
2000; 46(5):653-655. 
